NOT-MH-23-380: Notice of Need to Expire and Reissue of RFA-MH-24-160, RFA-MH-24-161 and RFA-MH-24-162 "Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (Clinical Trial Optional R01, R21 and R34)"

Notice of Need to Expire and Reissue of RFA-MH-24-160, RFA-MH-24-161 and RFA-MH-24-162 "Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (Clinical Trial Optional R01, R21 and R34)"

Notice Number:

NOT-MH-23-380

Key Dates

Release Date:

September 20, 2023

Related Announcements

August 25, 2023 - Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional). See RFA-MH-24-160
August 25, 2023 - Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional). See RFA-MH-24-161
August 25, 2023 - Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional). See RFA-MH-24-162

Issued by

National Institute of Mental Health (NIMH)

Purpose

The purpose of this Notice is to alert applicants of the early expiration of RFA-MH-24-160, “Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional)”, RFA-MH-24-161, “Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional)” and RFA-MH-24-162, Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional). The request for applications, RFA-MH-24-160, RFA-MH-25-161 and RFA-MH-24-162 will be expired effective immediately. No further applications will be accepted for consideration under these NOFOs.

A new RFAs to support “Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01, R21 and R34 Clinical Trial Optional)” will be issued to correct the section V language.

Applicants are encouraged to consider applying to the new NOFOs: RFA-MH-24-330, "Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional)", RFA-MH-24-331, "Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional)" and RFA-MH-24-332, “Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional)”.

Inquiries

Please direct all inquiries to:

Teri Senn, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-605-4146
Email: teri.senn@nih.gov